Authors: von der Thusen J, van der Eerden M PMID: 32353898 PMCID: PMC7267318 DOI: 10.1111/eci.13259 Abstract Background: The clinical features of COVID-19 pneumonia range from a mild illness to patients with a very severe illness with acute hypoxemic respiratory failure requiring ventilation and Intensive Care Unit admission. Aims: To provide a brief overview of the [...]

Authors: Mario L, Roberto M, Marta L, Teresa CM, Laura M PMID: 32939238 PMCID: PMC7478270 doi: 10.4103/ijpvm.IJPVM_258_20 Abstract Backgound: Bacterial or viral infections often cause acute and severe systemic inflammation, which affects the lungs lipopolysaccharide (LPS), a pathogenic component of the membrane of gram-negative bacteria, stimulates active innate immune cells, monocytes, macrophages to produce inducible [...]

Authors: Rahman MT PMID: 32834942 doi: 10.1016/j.hermed.2020.100382 Abstract An effective vaccine to prevent the SARS-CoV-2 causing COVID-19 is yet to be approved. Further there is no drug that is specific to treat COVID-19. A number of antiviral drugs such as Ribavirin, Remdesivir, Lopinavir/ritonavir, Azithromycin and Doxycycline have been recommended or are being used to treat [...]

Authors: Brosnahan SB, Bhatt A, Berger JS, Yuriditsky E, Iturrate E PMID: 32589950 PMCID: PMC7309731 DOI: 10.1016/j.chest.2020.06.023 Abstract VTE is an important, dangerous, and sometimes fatal complication of coronavirus disease 2019 (COVID-19). Thrombosis, including ischemic heart disease and stroke, contributes to the overall disease burden in all non-COVID patient populations worldwide, accounting for approximately one [...]

Authors: Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M PMID: 32585284 PMCID: PMC7308750 DOI: 10.1016/j.ijid.2020.06.064 Abstract Objective: To evaluate the therapeutic use of plasma exchange in COVID-19 patients compared to controls. Methods: A case series of critically ill adult men and non-pregnant women, ≥18 years of age, with laboratory-confirmed COVID-19, [...]

Authors: Wessel L Abstract Researchers accused of killing patients after using a high dose to treat coronavirus infection Keywords: COVID-19, SARS-CoV2 Source: https://www.science.org/content/article/it-s-nightmare-how-brazilian-scientists-became-ensnared-chloroquine-politics Archive: https://archive.is/sD9SZ

Authors: Schultze A, Walker AJ, MacKenna B, Morten CE, Bhaskaran K, Brown JP doi: https://doi.org/10.1101/2020.06.19.20135491 Abstract Background Early descriptions of the coronavirus outbreak showed a lower prevalence of asthma and COPD than was expected for people diagnosed with COVID-19, leading to speculation that inhaled corticosteroids (ICS) may protect against infection with SARS-CoV-2, and development of [...]

Authors: Parry AH, Wani AH, Shah NN, Yaseen M, Jehangir M PMID: 33178976 PMCID: PMC7594891 DOI: 10.1259/bjro.20200016 Abstract Objective: To study the spectrum of chest CT features in coronavirus disease-19 (COVID-19) pneumonia and to identify the initial CT findings that may have the potential to predict a poor short-term outcome. Methods: This was a retrospective [...]

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an emergent global threat which is straining worldwide healthcare capacity. As of May 27th, the disease caused by SARS-CoV-2 (COVID-19) has resulted in more than 340,000 deaths worldwide, with 100,000 deaths in the US alone. It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19. Ascorbic acid is a crucial vitamin necessary for the correct functioning of the immune system. It plays a role in stress response and has shown promising results when administered to the critically ill. Quercetin is a well-known flavonoid whose antiviral properties have been investigated in numerous studies. There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy. Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic. We present the current evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients as an adjunct to promising pharmacological agents such as Remdesivir or convalescent plasma.

Authors: Li S, Jiang L, Li X, Lin F, Wang Y, Li B PMID: 32427582 PMCID: PMC7406259 DOI: 10.1172/jci.insight.138070 Abstract Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), has become a pandemic. This study addresses the clinical and immunopathological characteristics of severe COVID-19. Methods: Sixty-nine patients with COVID-19 were classified [...]